Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

Trial Details

NCT ID
NCT04198766
Phase
PHASE1 / PHASE2
Sponsor
Inhibrx Biosciences, Inc
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • INBRX-106 - Hexavalent OX40 agonist antibody
  • pembrolizumab 200 mg
  • pembrolizumab 400 mg
  • Carboplatin AUC-5
  • Carboplatin AUC-6
  • Pemetrexed 500 mg/m2
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Glendale, California, United States|34.14251,-118.25508
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Murrieta, California, United States|33.55391,-117.21392

Key Eligibility Criteria

  • Males or females aged ≥18 years.
  • Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite …
  • Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced o…
  • Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →